Bachem Holding AG stock (CH0012530207): Peptide specialist with US exposure trades near 52?week range

Bachem Holding AG shares trade near the upper end of their 52?week range as the peptide and oligonucleotide specialist continues to serve global pharma and biotech clients.

Bachem Holding AG shares are trading near the upper end of their 52?week range, reflecting continued investor interest in the Swiss peptide and oligonucleotide specialist that serves pharmaceutical and biotechnology companies worldwide, according to market data as of early May 2026.

On the SIX Swiss Exchange, Bachem Holding AG (ticker: BANB) trades in the mid?70s in Swiss francs, close to the 76.00?franc high of the past 52 weeks, while the low stands at about 43.34 francs, per Morningstar data updated in 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Basic Materials / Chemicals
• Headquarters/country: Switzerland
• Core markets: Europe, Asia, United States
• Key revenue drivers: Peptides and oligonucleotides for research, clinical development and commercial applications
• Home exchange/listing venue: SIX Swiss Exchange (BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG operates as a biochemical company focused on the development and manufacture of peptides and oligonucleotides for pharmaceutical and biotechnology clients, according to its investor?relations profile and third?party overviews.

The group markets its products under the Bachem and Clinalfa brands and provides services across the drug lifecycle, from early?stage research through clinical development to commercial supply, which positions it as a contract development and manufacturing organization (CDMO) in the peptide and oligonucleotide space.

Bachem’s business is organized into geographic segments Europe/Asia and USA, underscoring its global footprint and exposure to both European and North American pharmaceutical markets.

Main revenue and product drivers for Bachem Holding AG

Bachem’s main revenue streams stem from its CMC Development, Commercial API, Research and Specialities, and Services and Capabilities offerings, which together support customers in research, clinical trials and commercial production.

Peptides and oligonucleotides are increasingly important modalities in modern drug development, including in oncology, metabolic diseases and rare conditions, which helps sustain demand for Bachem’s specialized manufacturing and analytical capabilities.

Why Bachem Holding AG matters for US investors

For US investors, Bachem Holding AG offers indirect exposure to the peptide and oligonucleotide CDMO segment through its unsponsored ADR listed over?the?counter under the symbol BCHMY, which trades in US dollars and is quoted on major US data platforms.

With a dedicated USA segment and services tailored to global pharma and biotech clients, Bachem’s performance is linked to R&D spending and outsourcing trends in the US biopharma industry, making it relevant for investors seeking niche exposure beyond large?cap US?listed CDMOs.

Conclusion

Bachem Holding AG operates in a specialized niche within the biochemical and CDMO landscape, focusing on peptides and oligonucleotides that are central to many modern drug programs.

The company’s global footprint, including a dedicated USA segment and an unsponsored ADR for US investors, links its fortunes to broader trends in biopharma outsourcing and peptide?based therapeutics.

While valuation metrics such as a price?to?earnings ratio in the low?40s and a price?to?sales ratio above 8 suggest a premium valuation, Bachem’s positioning in a growing modality segment may support continued investor interest, though risks include competition, regulatory scrutiny and project?specific demand swings.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.